|Articles|April 2, 2015

Certara Launches Cardiac Safety Simulator V2.0

Author(s)Applied Clinical Trials Editorial Staff

Certara®, a global biosimulation technology-enabled consultancy, announced version 2.0 of its Cardiac Safety Simulator (CSS), which has become a standalone product for the first time. CSS is an alternative to Thorough QT/QTc (TQT) studies.

Certara®, a global biosimulation technology-enabled consultancy, announced version 2.0 of its Cardiac Safety Simulator (CSS), which has become a standalone product for the first time. CSS is an alternative to Thorough QT/QTc (TQT) studies. CSS uses drug-triggered cardiac ion-current disruption data, together with predicted in-vivo exposure information to evaluate the factors influencing potential cardiac risk.

CSS v2.0 offers new features including the following:

Enhanced QSAR models for predicting drug-triggered IKr, IKs, INa and ICaL current inhibition based on automatically-calculated phys-chem data (when in-vitro data are not available)

Predicts population variability and drug-triggered physiology modifications

Permits assessment of the potential impact of disease and genotypes; allows for genotype-related ionic current modification at the multiple channels level

Contains an additional human left ventricular muscle cell model

Evaluates up to seven chemical species (drugs, metabolites and other substances) simultaneously that are interacting at the ion channel(s) level

Provides a new flexible, Excel-based tool to enhancevisualization and analysis of simulation results

Read the full release.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!